TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$198.7 Million

Tyra Biosciences, Inc.

Initial Public Offering

Bookrunner, September 2021

Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅP shots, in order to generate next-generation product candidates that are specifically designed to address acquired drug restyraistance and provide alternative treatment options. Their lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.